Government-Owned Inventions; Availability for Licensing, 35372-35373 [2016-12892]

Download as PDF 35372 Federal Register / Vol. 81, No. 106 / Thursday, June 2, 2016 / Notices Dated: May 27, 2016. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–12998 Filed 6–1–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings asabaliauskas on DSK3SPTVN1PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c) (6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR13–280: Program Project: Mechanisms of Membrane Fusion. Date: June 14, 2016. Time: 12:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting). Contact Person: David R Jollie, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4150, MSC 7806, Bethesda, MD 20892, (301)-435– 1722, jollieda@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Brain Disorders and Clinical Neuroscience Integrated Review Group; Clinical Neuroplasticity and Neurotransmitters Study Section. Date: June 16–17, 2016. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Renaissance Mayflower Hotel, 1127 Connecticut Avenue NW., Washington, DC 20036. Contact Person: Suzan Nadi, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5217B, MSC 7846, Bethesda, MD 20892, 301–435– 1259, nadis@csr.nih.gov. VerDate Sep<11>2014 20:01 Jun 01, 2016 Jkt 238001 This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Cardiovascular and Respiratory Sciences Integrated Review Group; Myocardial Ischemia and Metabolism Study Section. Date: June 23–24, 2016. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814 Contact Person: Kimm Hamann, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4118A, MSC 7814, Bethesda, MD 20892, 301–435– 5575, hamannkj@csr.nih.gov. Name of Committee: Brain Disorders and Clinical Neuroscience Integrated Review Group; Developmental Brain Disorders Study Section. Date: June 23–24, 2016. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Melrose Hotel, 2430 Pennsylvania Avenue NW., Washington, DC 20037. Contact Person: Pat Manos, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5200, MSC 7846, Bethesda, MD 20892, 301–408– 9866, manospa@csr.nih.gov. Name of Committee: Oncology 2— Translational Clinical Integrated Review Group; Chemo/Dietary Prevention Study Section. Date: June 23–24, 2016. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Warwick Seattle Hotel, 401 Lenora Street, Seattle, WA 98121. Contact Person: Svetlana Kotliarova, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6214, Bethesda, MD 20892, 301–594–7945, kotliars@mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Drug Discovery and Mechanisms of Antimicrobial Resistance. Date: June 23, 2016. Time: 1:00 p.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: American Inn of Bethesda, 8130 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: John C Pugh, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1206, MSC 7808, Bethesda, MD 20892, (301) 435– 2398, pughjohn@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS) PO 00000 Frm 00080 Fmt 4703 Sfmt 4703 Dated: May 26, 2016. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–12898 Filed 6–1–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health. Notice. AGENCY: ACTION: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892–2479; telephone: 301–402–5579. A signed Confidential Disclosure Agreement may be required to receive any unpublished information. SUPPLEMENTARY INFORMATION: Technology description follows. SUMMARY: Albumin Binding Immunomodulatory Compositions The invention relates to molecules wherein Evan’s Blue dye is chemically conjugated to CpG Oligonucleotides that elicit anti-tumoral or infection fighting immunity. Evans Blue, a symmetric azo dye, has high binding affinity to albumin. Albumin binding ability of Evans blue is utilized with CpGs and tumor-specific antigens, in order to leverage endogenous albumin that increases the safety and the potency of molecular vaccines. As such, the molecular entities provided here enable efficient delivery and prolonged retention in lymph nodes and reduce systemic toxicity of Evans Blue and enhanced the therapeutic potency of molecular vaccines. Potential Commercial Applications: • Cancer therapeutics • Infectious disease therapeutics • Lymph node specificity • Higher stability/Lower toxicity Development Stage: • Early stage E:\FR\FM\02JNN1.SGM 02JNN1 35373 Federal Register / Vol. 81, No. 106 / Thursday, June 2, 2016 / Notices Inventors: Xiaoyuan Chen and Guizhi Zhu (both of NIBIB). Intellectual Property: HHS Reference No. E–149–2016/0; U.S. Provisional Patent Applications 62/331,890 filed May 4, 2016. Licensing Contact: Michael Shmilovich, Esq, CLP; 301–435–5019; shmilovm@mail.nih.gov. Dated: May 26, 2016. Michael Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. [FR Doc. 2016–12892 Filed 6–1–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Submission for OMB Review; 30-Day Comment Request; The Study of Center of Global Health’s (CGH) Workshops (NCI) Under the provisions of Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Cancer Instititue, the National Institutes of Health, has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below. This proposed information collection was previously published in the Federal Register on March 1, 2016 and page 10638 and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Cancer Institute, NCI, National Institutes of Health, may not conduct or sponsor, and the SUMMARY: respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number. Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, OIRA_submission@ omb.eop.gov or by fax to 202–395–6974, Attention: NIH Desk Officer. DATES: Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication. FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data collection plans and instruments, or request more information on the proposed project, contact*: Sudha Sivaram, National Cancer Institute Center for Global Health, 9609 Medical Center Dr., Rm 3W528, Rockville, MD 20850 or call non-toll-free number (240) 276–5815 or Email your request, including your address to: sudha.sivaram@nih.gov. Formal requests for additional plans and instruments must be requested in writing. Proposed Collection: The Study of the Center of Global Health’s (CGH) Workshops (NCI), 0925–0722, Expiration Date 06/30/2018, REVISION, National Cancer Institute (NCI), National Institutes of Health (NIH). Need and Use of Information Collection: This study is collecting stakeholder feedback from past and future workshops; to assess the effectiveness of the Center of Global Health (CGH) workshops, which seek to assess abilities of the workshop attendees and respective countries to implement national cancer control programs; inform content and improve delivery of future workshops, and to systematically assess CGH’s contribution. The workshops to be studied are the Symposiums on Global Cancer Research, Workshops in Cancer Control Planning and Implementation, the Summer Curriculum in Cancer Prevention, Women’s Cancer Program Summit, Regional Grant Writing and Peer Review Workshops, and Workshops on Tobacco Control. While these workshops differ in content and delivery style, their underlying goals are the same; they intend to initiate and enhance cancer control efforts, increase capacity for cancer research, foster new partnerships, and create research and cancer control networks. The proposed study requests information about the outcomes of each of these workshops including (1) new cancer research partnerships and networks (2) cancer control partnerships and networks, (3) effects on cancer research, and (4) effect on cancer control planning and implementation efforts. Information will be collected in two phases where Phase 1 will collect information from attendees of past workshops (1998– 2015) and Phase 2 will collect information from attendees of future workshops over the next three years. The surveys will enable CGH to better understand the impact the workshops have had on their partnerships and networks, research, and cancer control planning and implementation efforts. OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 941. ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents per year Form name Chief Executives, Medical Scientists, Health Educators, Family/General Practitioners, Registered Nurses, Medical and Health Services Managers. asabaliauskas on DSK3SPTVN1PROD with NOTICES Type of respondents Phase 1: Symposium on Global Cancer Research. Phase 2: Symposium on Global Cancer Research. Phase 1: Workshop in Cancer Control Planning and Implementation for non-Ministry of Health participants. Phase 2: Workshop in Cancer Control Planning and Implementation for non-Ministry of Health participants. Phase 1: Workshop in Cancer Control Planning and Implementation for Ministry of Health. VerDate Sep<11>2014 20:01 Jun 01, 2016 Jkt 238001 PO 00000 Frm 00081 Fmt 4703 Sfmt 4703 Number of responses per respondent Average burden per response (in hours) Total annual burden hours 500 1 20/60 167 250 1 20/60 84 70 1 20/60 23 70 1 20/60 23 70 1 20/60 23 E:\FR\FM\02JNN1.SGM 02JNN1

Agencies

[Federal Register Volume 81, Number 106 (Thursday, June 2, 2016)]
[Notices]
[Pages 35372-35373]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-12892]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY:  National Institutes of Health.

ACTION:  Notice.

-----------------------------------------------------------------------

SUMMARY:  The inventions listed below are owned by an agency of the 
U.S. Government and are available for licensing in the U.S. in 
accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve 
expeditious commercialization of results of federally-funded research 
and development.

FOR FURTHER INFORMATION CONTACT:  Licensing information may be obtained 
by emailing the indicated licensing contact at the National Heart, 
Lung, and Blood, Office of Technology Transfer and Development Office 
of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, 
MD 20892-2479; telephone: 301-402-5579. A signed Confidential 
Disclosure Agreement may be required to receive any unpublished 
information.

SUPPLEMENTARY INFORMATION:  Technology description follows.

Albumin Binding Immunomodulatory Compositions

    The invention relates to molecules wherein Evan's Blue dye is 
chemically conjugated to CpG Oligonucleotides that elicit anti-tumoral 
or infection fighting immunity. Evans Blue, a symmetric azo dye, has 
high binding affinity to albumin. Albumin binding ability of Evans blue 
is utilized with CpGs and tumor-specific antigens, in order to leverage 
endogenous albumin that increases the safety and the potency of 
molecular vaccines. As such, the molecular entities provided here 
enable efficient delivery and prolonged retention in lymph nodes and 
reduce systemic toxicity of Evans Blue and enhanced the therapeutic 
potency of molecular vaccines.

Potential Commercial Applications:
 Cancer therapeutics
 Infectious disease therapeutics
 Lymph node specificity
 Higher stability/Lower toxicity
Development Stage:
 Early stage


[[Page 35373]]


    Inventors: Xiaoyuan Chen and Guizhi Zhu (both of NIBIB).
    Intellectual Property: HHS Reference No. E-149-2016/0; U.S. 
Provisional Patent Applications 62/331,890 filed May 4, 2016.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
shmilovm@mail.nih.gov.

    Dated: May 26, 2016.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2016-12892 Filed 6-1-16; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.